Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like HonorHealth taps longevity authority Nicholas J. Schork to lead new research division August 14, 2025 Type 2 diabetes diagnosis at age 30 can reduce life expectancy by up to 14 years October 3, 2023 Study finds Brain Care Score as a strong predictor of stroke across racial groups December 18, 2025
HonorHealth taps longevity authority Nicholas J. Schork to lead new research division August 14, 2025